Clinical ResearchAngiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes)
Key Words
Abbreviations and Acronyms
Cited by (0)
The PLATO trial was funded by AstraZeneca. Dr. Kunadian has received research support and honoraria from Eli Lilly/Daiichi Sankyo, Abbott Vascular, and The Medicines Company. Dr. James has received institutional research grant and/or honoraria from AstraZeneca, Eli Lilly, Merck & Co., Inc., Bristol-Myers Squibband The Medicines Company; and served as an advisory board member for AstraZeneca, Eli Lilly, and Merck & Co., Inc. Dr. Storey has received research grants from AstraZeneca, Eli Lilly/Daiichi Sankyo, and Merck & Co. Inc.; research support from Accumetrics; honoraria from AstraZeneca, Eli Lilly/Daiichi Sankyo, Merck & Co. Inc., Novartis, The Medicines Company, Iroko, sanofi-aventis/Regeneron, Bristol-Myers Squibb, Accumetrics, Medscape, and Eisai; and consultancy fees from AstraZeneca, Merck & Co. Inc., Novartis, Accumetrics, and Eisai. Dr. Steg has received research grants from New York University School of Medicine, sanofi-aventis, and Servier; has received consulting fees/honoraria from Ablynx, Amarin, Amgen, Astellas, AstraZeneca, Bayer HealthCare, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, GlaxoSmithKline, Lilly, Medtronic, Merck & Co., Inc., Merck, Sharp, and Dohme, Novartis, Otsuka, Pfizer, Inc., Roche Diagnostics, sanofi-aventis, Servier, The Medicines Company, and Vivus; and has equity ownership in Aterovax. Dr. Katus has received consulting and lecture fees from AstraZeneca. Drs. Emanuelsson, Horrow, and Maya are equity-owning employees of AstraZeneca. Dr. Wallentin has received research grants from AstraZeneca, Merck & Co., Inc., Schering-Plough, Boehringer-Ingelheim, Bristol-Myers Squibb, Pfizer, Inc., and GlaxoSmithKline; consulting fees from Merck & Co., Inc., Schering-Plough, Regado Biosciences, Evolva, Portola Pharmaceuticals, C.S.L. Behring, Athera Biotechnologies, Boehringer-Ingelheim, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, and Pfizer, Inc.; lecture fees from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Pfizer, Inc., GlaxoSmithKline, Merck & Co., Inc., and Schering-Plough; honoraria from Boehringer-Ingelheim, AstraZeneca, Bristol-Myers Squibb, Pfizer, Inc., GlaxoSmithKline, Merck & Co., Inc., and Schering-Plough; and travel support from Bristol-Myers Squibb and Pfizer, Inc. Dr. Harrington has received consulting fees from Bristol-Myers Squibb, sanofi-aventis, Portola Pharmaceuticals, Schering-Plough, and AstraZeneca; lecture fees from Schering-Plough, Bristol-Myers Squibb, sanofi-aventis, and Eli Lilly; grant support from Merck & Co., Inc., Millennium Pharmaceuticals, Schering-Plough, The Medicines Company, Portola Pharmaceuticals, Regado Biosciences, AstraZeneca, and Bristol-Myers Squibb; has served on the advisory boards of WebMD, Gilead Sciences, Merck & Co., Inc., Regado Biosciences, and Johnson & Johnson. Dr. Gibson has received research grant support from AstraZeneca, Eli Lilly, and sanofi-aventis; and consulting fees and honoraria from Eli Lilly and sanofi-aventis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.